Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) FCF Margin (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed FCF Margin for 14 consecutive years, with 24.12% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 625.0% to 24.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.11%, a 142.0% decrease, with the full-year FY2025 number at 3.26%, down 63.0% from a year prior.
  • FCF Margin was 24.12% for Q4 2025 at Aytu Biopharma, up from 4.45% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 30.49% in Q2 2023 to a low of 38.15% in Q4 2021.
  • A 5-year average of 5.95% and a median of 7.65% in 2024 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: crashed -5470bps in 2022, then soared 5626bps in 2023.
  • Aytu Biopharma's FCF Margin stood at 38.15% in 2021, then soared by 75bps to 9.47% in 2022, then skyrocketed by 92bps to 0.72% in 2023, then soared by 2582bps to 17.87% in 2024, then skyrocketed by 35bps to 24.12% in 2025.
  • Per Business Quant, the three most recent readings for AYTU's FCF Margin are 24.12% (Q4 2025), 4.45% (Q3 2025), and 18.41% (Q2 2025).